Suvorexant proposed for double-blind trial to manage comorbid insomnia and alcohol dependence, targeting withdrawal and abstinence.
Background
Alcohol use disorder (AUD) frequently co-occurs with insomnia, affecting 36-72% of individuals. Sleep disturbances persist for months during abstinence and strongly predict relapse. Current treatments often fall short in addressing this dual burden. Orexins, neuropeptides involved in reward and addiction, play a critical role in both alcohol withdrawal and cue-triggered alcohol seeking via OX1 and OX2 receptor signaling, presenting a novel therapeutic target.
Study Design
This proposal outlines the first double-blind controlled trial to evaluate suvorexant in patients with alcohol dependence. The study aims to assess its safety and efficacy for treating sleep disorders during acute alcohol withdrawal and for six months post-withdrawal. Primary endpoints include improvements in sleep, reduction in alcohol craving, and promotion of abstinence duration. The trial will compare suvorexant against a control arm, though specific doses or patient numbers (n) are not detailed in this proposal.
Why It Matters
If successful, this trial could establish suvorexant as a critical pharmacotherapy for alcohol use disorder patients, addressing the significant challenge of comorbid insomnia and its link to relapse. This would offer a novel, targeted approach beyond current standard-of-care for managing withdrawal-related sleep disturbances and maintaining long-term abstinence. The findings could inform new clinical protocols for integrating orexin receptor antagonists into addiction treatment strategies, potentially improving patient outcomes and reducing relapse rates.
suvorexant
alcohol-dependence
insomnia
orexin-antagonist
sleep-disorder
addiction